[Intravenous administration of deferoxamine in over-night hospitalization: efficacy and good psychological tolerance in thalassemic children].
Daily subcutaneous infusion of deferoxamine in thalassemia and other transfusion dependent-patients can successfully treat iron overload, but most patients, mainly young children and teenagers may not comply with this method. Experience with nightly intravenous infusion of deferoxamine (8 g) through a subcutaneous-port over 5 out of 21 days, is reported in 4 children with dramatic improvement in clinical status, ferritin levels and quality of life.
Bachelot
C
C
Unité d'hématologie-oncologie pédiatrique (services de pédiatrie des Prs A Baudoing et M Bost), Centre hospitalier de Grenoble, France.
Plantaz
D
D
D000293:Adolescent; D002648:Child; D002673:Child, Hospitalized / Q000523:psychology; D003676:Deferoxamine / Q000008:administration & dosage* / Q000627:therapeutic use; D005500:Follow-Up Studies; D006801:Humans; D015918:Infusion Pumps, Implantable / Q000523:psychology; D007262:Infusions, Intravenous; D009551:Night Care / Q000523:psychology; D013789:Thalassemia / Q000188:drug therapy*
D003676:Deferoxamine
Administration intraveineuse de desférioxamine en hospitalisation de nuit: efficacité et bonne tolérance psychologique pour les enfants thalassémiques.